# idiopathic pulmonary fibrosis (IPF) - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 42322
- Completion tokens: 36911
- Reasoning tokens: 13051
- Total tokens: 79233
- API requests reported: 3
- Elapsed seconds: 50.488
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1387.824
- Question handoff seconds: 1401.194
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: Google Gemini

---
### 1. Data Quality Warning & Overall Biological Interpretation

#### Data Quality and Technical Caveats
A review of the input statistical ledger reveals notable numerical anomalies in a subset of features:
* **Extreme Numerical Artifacts:** Features such as `MIR221`, `IHH`, `FAM75A2`, `OR2M2`, `XLOC_003303`, and `DYDC2` display degenerate hazard ratios ($\text{HR} = 1.93 \times 10^{-22}$, $P = 0$, $\text{FDR} = 0$), while probes such as `CONTROL_A_33_P3222196`, `HCN4`, `CONTROL_A_33_P3345409`, and `DKFZP434L187` display unbiologically high estimates ($\text{HR} = 5.18 \times 10^{21}$, $P = 0$, $\text{FDR} = 0$).
* **Control and Non-Coding Probes:** The dataset includes microarray internal control probes (`CONTROL_A_33_...`) and unannotated long non-coding RNAs (`lincRNA:chr2:...`).
* **Interpretation Approach:** These extreme coefficients likely stem from numerical instability (e.g., separation in Cox regression models, unadjusted probe background noise, or probe saturation). Consequently, these specific statistical extreme values are treated as unreliable direct statistical evidence. The remaining 93 risk-associated and 7 protective-associated genes with valid finite hazard ratios form the basis of the primary biological synthesis below.

#### Overall Biological Synthesis
The transcriptomic profile of lung tissue associated with all-cause mortality in idiopathic pulmonary fibrosis (IPF) is overwhelmingly dominated by **risk-associated features** (93 out of 100 selected unique genes exhibit $\text{HR} > 1.0$). Rather than isolated gene alterations, the data reflect a coordinated, multi-cellular disease program characterized by:
1. **Persistent Neutrophilic Influx & Innate Chemokine Signaling:** Upregulation of neutrophil chemoattractants (`CXCL1`, `CCL7`, `CXCL14`), receptors (`CXCR1`), and granule/activation proteins (`S100A12`, `MMP25`, `CD177`).
2. **Pathological Matrix Remodeling & Fibrotic Niche Architecture:** Overexpression of pericellular proteases (`HTRA1`, `MMP25`), matricellular signaling glycoproteins (`SPP1`, `EFEMP1`), and proteoglycan modifying enzymes (`CHST15`).
3. **Dysregulated Epithelial–Mesenchymal RTK Signaling:** Activation of growth factor signaling axes, notably `HGF` and its receptor `MET`, along with feedback regulators (`SPRY2`, `NRG1`) and macrophage phagocytic receptors (`MERTK`).
4. **Alveolar Epithelial Secretory & Surfactant Dysfunction:** Increased expression of alveolar epithelial and mucin markers (`MUC1`, `MUC21`, `SFTPB`, `SFTA2`, `SLC34A2`), indicating secretory cell metaplasia and persistent alveolar injury.
5. **Actin Cytoskeletal Dynamics & Plasma Membrane Remodeling:** Elevation of membrane-cytoskeleton cross-linking proteins (`MARCKS`, `BASP1`, `KANK1`, `FBLIM1`), signaling focal adhesion turnover and migratory cell phenotypes.

---

### 2. Core Biological Programs

```
                       +-------------------------------------------------------+
                       |   IPF Lung Tissue Mortality Transcriptomic Architecture|
                       +-------------------------------------------------------+
                                                   |
      +-------------------+------------------------+-----------------------+-------------------+
      |                   |                        |                       |                   |
      v                   v                        v                       v                   v
+---------------+ +---------------+        +---------------+       +---------------+   +---------------+
| Program 1:    | | Program 2:    |        | Program 3:    |       | Program 4:    |   | Program 5:    |
| Neutrophil    | | Pericellular  |        | Epithelial-   |       | Distal Alveolar|   | Membrane-     |
| Chemotaxis &  | | ECM Remodeling|        | Mesenchymal   |       | Secretory &   |   | Cytoskeletal  |
| Granule Influx| | & Proteolysis |        | RTK Crosstalk |       | Mucinous Met. |   | Organization  |
+---------------+ +---------------+        +---------------+       +---------------+   +---------------+
| CXCL1, CXCR1, | | HTRA1, SPP1,  |        | HGF, MET,     |       | MUC1, MUC21,  |   | MARCKS, BASP1,|
| S100A12,      | | EFEMP1,       |        | MERTK, NRG1,  |       | SFTPB, SFTA2, |   | KANK1, FBLIM1,|
| MMP25, CCL7   | | CHST15, FHL2  |        | SPRY2         |       | SLC34A2       |   | ENAH, MTSS1   |
+---------------+ +---------------+        +---------------+       +---------------+   +---------------+
```

#### Program 1: Neutrophil Chemotaxis and Innate Granule Activation
* **Prognostic Association:** Risk-associated ($\text{HR} > 1.0$).
* **Major Supporting Genes:** `CXCL1` ($\text{HR} = 2.990$), `CXCR1` ($\text{HR} = 3.281$), `CCL7` ($\text{HR} = 3.016$), `S100A12` ($\text{HR} = 2.535$), `MMP25` ($\text{HR} = 3.256$), `CD177` ($\text{HR} = 2.716$), `PROK2` ($\text{HR} = 3.647$).
* **Standardized Pathway Alignment:** GO:1990266 (Neutrophil Migration); KEGG: hsa04062 (Chemokine signaling pathway).
* **Biological Rationale:** The concurrent hazard elevation of `CXCL1` and `CCL7` alongside their cognate receptor `CXCR1` directly reflects sustained recruitment of polymorphonuclear neutrophils into the fibrotic lung parenchyma. Co-expression of neutrophil-specific granule proteins (`S100A12`, `CD177`) and matrix metalloproteinase-25 (`MMP25`) demonstrates that active neutrophilic inflammation and degranulation strongly correlate with shortened survival in IPF.
* **Evidence Strength & Limitations:** High statistical consistency within the dataset ($\text{FDR} < 4 \times 10^{-5}$). *Limitation:* Tissue-level bulk RNA expression cannot distinguish whether increased chemokines originate from damaged epithelial cells, vascular endothelium, or infiltrating myeloid cells.

#### Program 2: Pericellular Matrix Remodeling and Fibrotic Niche Architecture
* **Prognostic Association:** Risk-associated ($\text{HR} > 1.0$).
* **Major Supporting Genes:** `HTRA1` ($\text{HR} = 4.302$), `SPP1` ($\text{HR} = 3.399$), `EFEMP1` ($\text{HR} = 2.329$), `CHST15` ($\text{HR} = 2.991$), `FHL2` ($\text{HR} = 2.764$), `TPST1` ($\text{HR} = 2.923$).
* **Standardized Pathway Alignment:** Reactome: R-HSA-1474244 (Extracellular matrix organization); GO:0030198 (Extracellular matrix organization).
* **Biological Rationale:** `HTRA1` (a pericellular serine protease) and `SPP1` (osteopontin, a key driver of myofibroblast activation and matrix deposition) are among the strongest individual risk predictors in the dataset. Together with extracellular matrix glycoprotein `EFEMP1` and sulfotransferase `CHST15` (which modifies chondroitin sulfate in fibrotic lesions), these genes mark active remodeling of the pulmonary extracellular matrix, mechanical stiffening, and irreversible architectural distortion.
* **Evidence Strength & Limitations:** Strong effect sizes ($\text{HR} = 2.33$–$4.30$). *Limitation:* Associations reflect late-stage matrix accumulation and tissue destruction; cause-versus-effect relationships regarding disease progression cannot be established from observational survival data.

#### Program 3: Epithelial–Mesenchymal Receptor Tyrosine Kinase (RTK) Crosstalk
* **Prognostic Association:** Risk-associated ($\text{HR} > 1.0$).
* **Major Supporting Genes:** `HGF` ($\text{HR} = 2.927$), `MET` ($\text{HR} = 2.526$), `MERTK` ($\text{HR} = 3.702$), `NRG1` ($\text{HR} = 2.757$), `SPRY2` ($\text{HR} = 3.263$).
* **Standardized Pathway Alignment:** Reactome: R-HSA-6800164 (Signaling by MET); KEGG: hsa04010 (MAPK signaling pathway).
* **Biological Rationale:** Hepatocyte growth factor (`HGF`) and its receptor `MET` form a classical paracrine axis governing epithelial repair, cell survival, and invasive growth. Elevated expression of both ligand and receptor, combined with feedback inhibitor `SPRY2` and neuregulin-1 (`NRG1`), indicates hyperactive growth factor signaling in damaged alveolar tissue. Concurrent elevation of `MERTK` highlights macrophage engagement in phagocytosis and TGF-$\beta$-inducing efferocytosis within the RTK microenvironment.
* **Evidence Strength & Limitations:** Co-elevation of ligand-receptor pairs (`HGF`–`MET`) provides internal coherence. *Limitation:* `HGF` is classically considered protective against experimental fibrosis in animal models; its elevated hazard in advanced human IPF lung tissue likely reflects a compensatory, uncoordinated repair response to severe destruction.

#### Program 4: Distal Alveolar Secretory Dysfunction and Mucinous Metaplasia
* **Prognostic Association:** Risk-associated ($\text{HR} > 1.0$).
* **Major Supporting Genes:** `MUC1` ($\text{HR} = 2.324$), `MUC21` ($\text{HR} = 2.103$), `SFTPB` ($\text{HR} = 2.665$), `SFTA2` ($\text{HR} = 2.248$), `SLC34A2` ($\text{HR} = 2.274$), `CEACAM6` ($\text{HR} = 2.658$).
* **Standardized Pathway Alignment:** Reactome: R-HSA-5683826 (Surfactant metabolism); GO:0005788 (Endoplasmic reticulum lumen / Secretory granule).
* **Biological Rationale:** The prognostic elevation of surfactant proteins (`SFTPB`, `SFTA2`) alongside transmembrane mucins (`MUC1`, `MUC21`) and epithelial transporters (`SLC34A2`) points to metabolic strain and phenotypic shift in alveolar type II (AT2) cells. Honeycombing and bronchiolization of the distal lung in advanced IPF are characterized by mucinous metaplasia and aberrant AT2-to-AT1 transdifferentiation.
* **Evidence Strength & Limitations:** Consistent direction across epithelial marker classes ($\text{HR} = 2.10$–$2.67$). *Limitation:* High expression of surfactant and mucin genes in tissue samples is highly dependent on local tissue sampling (e.g., dense fibrotic regions vs. honeycombed cysts vs. preserved parenchyma).

#### Program 5: Membrane-Cytoskeletal Organization and Actin Dynamics
* **Prognostic Association:** Risk-associated ($\text{HR} > 1.0$).
* **Major Supporting Genes:** `MARCKS` ($\text{HR} = 3.998$), `BASP1` ($\text{HR} = 3.772$), `KANK1` ($\text{HR} = 3.588$), `FBLIM1` ($\text{HR} = 2.591$), `ENAH` ($\text{HR} = 2.033$), `MTSS1` ($\text{HR} = 2.450$).
* **Standardized Pathway Alignment:** GO:0030036 (Actin cytoskeleton organization); GO:0005886 (Plasma membrane).
* **Biological Rationale:** `MARCKS` (myristoylated alanine-rich C-kinase substrate) and `BASP1` are acidic membrane-bound proteins that cross-link actin filaments and sequester PIP2, modulating cell motility and endocytosis. Their strong association with mortality ($\text{HR} \approx 3.8$–$4.0$), alongside focal adhesion regulator `KANK1` and actin elongation factor `ENAH`, reflects high cellular motility and cytoskeletal remodeling in fibrotic lung tissue.
* **Evidence Strength & Limitations:** High statistical significance ($\text{FDR} < 3 \times 10^{-5}$). *Limitation:* Functional interactions between MARCKS, BASP1, and focal adhesion complexes are inferred from general cell biology literature; tissue-specific interactions in IPF fibroblasts or macrophages require direct physical validation.

---

### 3. Key Genes and Interaction Modules

| Candidate / Module | Statistical Association | Biological Program | Molecular Nature of Relationship |
| :--- | :--- | :--- | :--- |
| **`HTRA1`** | Risk ($\text{HR} = 4.302$, $\text{FDR} = 2.571 \times 10^{-6}$) | ECM Remodeling | **Pathway Co-membership / Proteolytic activity:** Secreted serine protease that cleaves matrix proteins and modulates latent TGF-$\beta$ binding proteins in the extracellular space. |
| **`SPP1` (Osteopontin)** | Risk ($\text{HR} = 3.399$, $\text{FDR} = 3.991 \times 10^{-5}$) | ECM Remodeling / Macrophage Niche | **Pathway Co-membership / Extracellular binding:** STRING network indicates interactions with integrins, `CD44`, and `FN1`. Acts as a macrophage-derived fibrotic mediator. |
| **`HGF` – `MET` Module** | Both Risk (`HGF` $\text{HR} = 2.927$; `MET` $\text{HR} = 2.526$) | RTK Signaling | **Direct Physical Interaction (Ligand–Receptor Binding):** HGF binds directly to the MET cell-surface receptor tyrosine kinase to activate downstream RAS/MAPK and PI3K pathways. |
| **`S100A12`** | Risk ($\text{HR} = 2.535$, $\text{FDR} = 5.486 \times 10^{-6}$) | Neutrophil Chemotaxis | **Pathway Co-membership / Receptor Binding:** Interacts with AGER (RAGE) and TLR4 (STRING confidence $>0.97$) to induce pro-inflammatory NF-$\kappa$B signaling. |
| **`CXCR1` – `CXCL1` – `CCL7` Chemokine Cluster** | All Risk (`CXCR1` $\text{HR} = 3.281$; `CXCL1` $\text{HR} = 2.990$; `CCL7` $\text{HR} = 3.016$) | Neutrophil Influx | **Pathway Co-membership & Ligand–Receptor Interaction:** CXCL1 binds directly to CXCR1 on neutrophils; CCL7 signals via CCR2/CCR3. Co-elevated in recruitment cascades. |
| **`MARCKS` – `BASP1` Module** | Both Risk (`MARCKS` $\text{HR} = 3.998$; `BASP1` $\text{HR} = 3.772$) | Cytoskeletal Dynamics | **Co-expression & Pathway Co-membership:** Both are membrane-anchored PKC substrates binding calmodulin (`CALML4`/`CALML6`) and regulating actin dynamics; no direct physical binding between them is established. |
| **`MERTK`** | Risk ($\text{HR} = 3.702$, $\text{FDR} = 1.050 \times 10^{-5}$) | Macrophage Clearance / RTK | **Regulatory Interaction:** Receptor tyrosine kinase expressed on pro-resolving/pro-fibrotic macrophages regulating apoptotic cell clearance (efferocytosis) and secondary TGF-$\beta$ release. |
| **`MUC1` – `SFTPB` – `SFTA2` Epithelial Module** | All Risk (`MUC1` $\text{HR} = 2.324$; `SFTPB` $\text{HR} = 2.665$; `SFTA2` $\text{HR} = 2.248$) | Alveolar Epithelial Metaplasia | **Co-expression & Cell-type Co-membership:** Markers co-expressed in injured distal airway and alveolar epithelial cells undergoing mucinous metaplasia; no direct protein complex formation. |
| **`SLC7A11`** | Risk ($\text{HR} = 3.516$, $\text{FDR} = 1.094 \times 10^{-5}$) | Metabolic Stress / Ferroptosis | **Pathway Co-membership:** Cystine/glutamate antiporter (xCT system) interacting with `CD44` to maintain intracellular glutathione and suppress ferroptotic cell death under chronic oxidative stress. |
| **`MIR221` / `IHH` / Degenerate Artifact Set** | Protective ($\text{HR} = 1.929 \times 10^{-22}$, $P = 0$) | Technical / Numerical Artifact | **Indirect / Unresolved Relationship:** Represent mathematical artifacts (zero-variance/complete separation) in model fitting rather than physiological protective mechanisms. |

---

### 4. High-Priority Validation Directions

#### Priority 1: Cell Composition Deconvolution and Spatial Mapping of Epithelial/Myeloid Signatures
* **Classification:** Confounding or composition check.
* **Prioritization Rationale:** Bulk RNA sequencing of whole lung tissue conflates cell-autonomous gene up-regulation with shifts in cellular proportions (e.g., loss of capillary endothelial cells vs. expansion of myofibroblasts and neutrophilic infiltrates).
* **Dataset Evidence:** Concurrent elevation of cell-type specific markers for neutrophils (`CD177`, `S100A12`), AT2 cells (`SFTPB`, `SFTA2`), mucinous cells (`MUC1`), and macrophages (`MERTK`, `SPP1`).
* **External Evidence:** Single-cell RNA-seq atlases of IPF lungs confirm distinct cell-type restriction for `SPP1` (macrophages) and `MUC1`/`SFTPB` (epithelial subsets).
* **Next Steps for Validation:** Apply computational deconvolution algorithms (e.g., CIBERSORTx) to bulk profiles, followed by multiplexed single-molecule FISH or spatial transcriptomics on formal-fixed paraffin-embedded (FFPE) IPF lung explants.
* **Evidence Status:** **Established hypothesis** (compositional confounding is a universally recognized property of bulk pulmonary transcriptomics).

#### Priority 2: Prognostic Utility of a Neutrophilic Activation Panel (`S100A12`, `CXCR1`, `MMP25`) in Fluid Biomarkers
* **Classification:** Biomarker.
* **Prioritization Rationale:** Non-invasive biomarkers capable of predicting rapid lung function decline or mortality in IPF are critically needed for patient stratification.
* **Dataset Evidence:** `CXCR1` ($\text{HR} = 3.281$), `S100A12` ($\text{HR} = 2.535$), and `MMP25` ($\text{HR} = 3.256$) display strong risk associations with low false discovery rates ($\text{FDR} < 1.3 \times 10^{-5}$).
* **External Evidence:** Serum and bronchoalveolar lavage (BAL) fluid concentrations of S100A12 and neutrophil-derived chemokines have been linked to disease severity in independent interstitial lung disease cohorts.
* **Next Steps for Validation:** Measure protein concentrations of S100A12, MMP25, and CXCL1 via ELISA in prospective serum and BAL cohorts, testing independent additive prognostic value over baseline forced vital capacity (FVC) and DLCO.
* **Evidence Status:** **Supported hypothesis** (requires formal prospective clinical validation; external statistical validation was not performed on this dataset).

#### Priority 3: Characterization of the `HGF`–`MET` Signaling Axis in Fibrotic Parenchyma
* **Classification:** Mechanistic hypothesis.
* **Prioritization Rationale:** The paradox of elevated HGF/MET expression correlating with mortality—despite HGF’s known antifibrotic actions in acute animal models—suggests impaired downstream signaling or receptor desensitization in end-stage IPF.
* **Dataset Evidence:** Co-elevation of ligand `HGF` ($\text{HR} = 2.927$), receptor `MET` ($\text{HR} = 2.526$), and negative feedback regulator `SPRY2` ($\text{HR} = 3.263$).
* **External Evidence:** Recombinant HGF inhibits myofibroblast differentiation *in vitro*, but truncated or inactive form accumulation occurs in fibrotic lung matrices.
* **Next Steps for Validation:** Quantify MET phosphorylation ($p$-MET) relative to total MET in primary human IPF fibroblasts and epithelial cells exposed to patient-derived matrix proteins.
* **Evidence Status:** **Exploratory hypothesis**.

#### Priority 4: Functional Impact of Macrophage `MERTK` Efferocytosis on Fibroblast Activation
* **Classification:** Therapeutic target.
* **Prioritization Rationale:** `MERTK` mediates macrophage clearance of apoptotic cells, a process that stimulates TGF-$\beta 1$ release and pro-fibrotic macrophage differentiation.
* **Dataset Evidence:** High statistical risk association ($\text{HR} = 3.702$, $\text{FDR} = 1.050 \times 10^{-5}$).
* **External Evidence:** MERTK inhibition reduces fibrotic remodeling in experimental liver and cardiac injury models, but its targeted role in human lung fibrosis remains unproven.
* **Next Steps for Validation:** Knock down or pharmacologically inhibit MERTK in human monocyte-derived macrophages co-cultured with primary IPF lung fibroblasts, measuring pro-collagen secretion.
* **Evidence Status:** **Exploratory hypothesis** (drug-target feasibility does not confirm clinical efficacy).

#### Priority 5: Independent External Cohort Validation of the Candidate Risk Score
* **Classification:** Biomarker / Methodological check.
* **Prioritization Rationale:** Overfitting and cohort-specific selection bias represent major risks in unvalidated transcriptomic survival signatures.
* **Dataset Evidence:** 100 features selected based on internal Cox regression coefficients.
* **External Evidence:** External statistical validation was not performed in the supplied analysis.
* **Next Steps for Validation:** Evaluate a weighted multivariable gene risk score constructed from the valid risk features (`HTRA1`, `SPP1`, `MARCKS`, etc.) in independent public microarray/RNA-seq cohorts (e.g., GEO GSE47460, GSE28042).
* **Evidence Status:** **Exploratory hypothesis** (pending independent statistical replication).

---

### 5. Multidimensional Evidence Grounding

```
+---------------------------------------------------------------------------------------------------+
|                                  EVIDENCE HIERARCHY ADJUDICATION                                  |
+---------------------------------------------------------------------------------------------------+
| 1. Direct Input Evidence    | Uploaded HR, P-values, FDRs (Authoritative for input cohort)        |
| 2. External Statistical Val.| Independent cohort statistics: ABSENT ("external statistical val.   |
|                             | was not performed")                                                 |
| 3. Pathway / Network / Lit. | Functional context only (Reactome, GO, STRING, PubMed); does not     |
|                             | constitute statistical replication or drug efficacy proof.          |
+---------------------------------------------------------------------------------------------------+
```

#### Evidence Hierarchy Mapping
1. **Direct Evidence from Input Dataset:**
   * Primary Cox regression metric: Hazard Ratio ($\text{HR}$) and False Discovery Rate ($\text{FDR}$).
   * Direct findings: 93 genes demonstrate risk association ($\text{HR} > 1.0$, $\text{FDR} < 10^{-4}$); 7 features display protective/extreme statistical artifacts ($\text{HR} < 1.0$).
2. **Pathway & Ontology Annotations (Contextual Knowledge):**
   * Standardized functional convergence mapped via GO (GO:1990266 Neutrophil Migration; GO:0030198 ECM Organization) and Reactome (R-HSA-1474244, R-HSA-6800164). These annotations reflect pre-existing database mappings, not new cohort-level enrichment $P$-values computed from raw matrices.
3. **Protein-Protein Interaction & Network Records:**
   * STRING database queries confirm functional/physical linkages for `HGF`–`MET` (direct binding) and `S100A12`–`AGER`/`TLR4` (receptor binding), as well as co-membership modules for `SPP1`–`CD44`–`FN1`.
4. **Published Literature Evidence:**
   * Literature confirms individual disease associations for `SPP1` (macrophage fibrotic marker), `HTRA1` (matrix degradation), `MUC1` (epithelial injury), and `S100A12` (neutrophil-driven inflammation).
5. **External Statistical Validation:**
   * **Status:** **External statistical validation was not performed.** No independent cohort statistics (e.g., validation $P$-values, hazard ratio concordance) were provided. Literature co-occurrence or pathway recurrence must not be confused with statistical cohort replication.

#### Overlapping vs. Independent Source Evaluation
* **Database Overlap Note:** QuickGO, Reactome, STRING, and OpenTargets share foundational underlying data from UniProt, PubMed, and Ensembl. High record counts across these platforms represent broad documentation across biomedical databases rather than multiple independent experimental validations.

---

### 6. Limitations and Alternative Explanations

1. **Cellular Heterogeneity and Tissue Composition Confounding:**
   * Whole-lung tissue transcriptomics measures the spatial sum of multiple cell types. Elevated risk signals for neutrophil genes (`S100A12`, `CXCR1`, `CD177`) or mucinous genes (`MUC1`, `MUC21`) may simply reflect an increased proportion of infiltrating inflammatory cells or honeycombed cyst lining in end-stage tissue rather than disease-causal cell-autonomous transcriptional activation.
2. **Degenerate Numerical Values and Statistical Separation:**
   * The presence of non-zero probes with extreme hazard ratios ($\text{HR} = 1.93 \times 10^{-22}$ and $5.18 \times 10^{21}$, $P = 0$) indicates mathematical separation (e.g., zero event counts in certain expression strata) or uncorrected background probe noise. Such features must be filtered prior to clinical risk score translation.
3. **Disease Severity vs. Mortality Causality Ambiguity:**
   * Transcriptomic survival analyses identify features correlated with overall survival, but cannot distinguish drivers of disease progression from markers of advanced structural damage or secondary terminal complications (e.g., acute exacerbation, pulmonary hypertension, or respiratory infection).
4. **Lack of Treatment and Clinical Risk Factor Adjustment:**
   * The dataset lacks covariates for antifibrotic medication exposure (nintedanib or pirfenidone), immunosuppressive therapy, smoking history, age, sex, or baseline forced vital capacity (FVC). Unmeasured treatment effects or clinical confounders could distort hazard ratio estimates for inducible metabolic or immune genes (`CYP4F3`, `SLC7A11`, `STEAP4`).
5. **Absence of External Independent Cohort Replication:**
   * Without independent statistical validation in a distinct, fully specified external validation cohort, all observed hazard associations remain exploratory hypotheses susceptible to single-center batch effects, platform-specific probe biases, and population-level overfitting.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=3, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 77/100 selected items (partially returned; some queries failed); cbioportal 78/100 selected items (records returned); chembl 13/100 selected items (partially returned; some queries failed); civic 8/100 selected items (records returned); clinicaltrials 48/100 selected items (records returned); clinvar 78/100 selected items (records returned); ensembl 25/100 selected items (partially returned; some queries failed); europepmc 860 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 78/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 81/100 selected items (partially returned; some queries failed); mygene 91/100 selected items (records returned); omnipath 47/100 selected items (records returned); opentargets 80/100 selected items (partially returned; some queries failed); pubmed 658 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 83/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 84/100 selected items (records returned)
Local databases: gutmgene 3/100 selected items (records returned); hmdb 32/100 selected items (records returned); string 79/100 selected items (records returned); trrust 25/100 selected items (records returned)
